| Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study AE Perl, JK Altman, J Cortes, C Smith, M Litzow, MR Baer, D Claxton, ... The Lancet Oncology 18 (8), 1061-1075, 2017 | 546 | 2017 |
| Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse M Levis, F Ravandi, ES Wang, MR Baer, A Perl, S Coutre, H Erba, ... Blood, The Journal of the American Society of Hematology 117 (12), 3294-3301, 2011 | 475 | 2011 |
| Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology MS Tallman, ES Wang, JK Altman, FR Appelbaum, VR Bhatt, D Bixby, ... Journal of the National Comprehensive Cancer Network 17 (6), 721-749, 2019 | 464 | 2019 |
| Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology MR O'Donnell, MS Tallman, CN Abboud, JK Altman, FR Appelbaum, ... Journal of the National Comprehensive Cancer Network 15 (7), 926-957, 2017 | 447 | 2017 |
| Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia CM McMahon, T Ferng, J Canaani, ES Wang, JJD Morrissette, ... Cancer discovery 9 (8), 1050-1063, 2019 | 406 | 2019 |
| Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm N Pemmaraju, AA Lane, KL Sweet, AS Stein, S Vasu, W Blum, DA Rizzieri, ... New England Journal of Medicine 380 (17), 1628-1637, 2019 | 402 | 2019 |
| Acute myeloid leukemia MR O'Donnell, CN Abboud, J Altman, FR Appelbaum, DA Arber, E Attar, ... Journal of the National Comprehensive Cancer Network 10 (8), 984-1021, 2012 | 390* | 2012 |
| Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. MA Caligiuri, C Murray, MJ Robertson, E Wang, K Cochran, C Cameron, ... The Journal of clinical investigation 91 (1), 123-132, 1993 | 327 | 1993 |
| Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial J Cortes, AE Perl, H Döhner, H Kantarjian, G Martinelli, T Kovacsovics, ... The Lancet Oncology 19 (7), 889-903, 2018 | 281 | 2018 |
| Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation RJ Soiffer, C Murray, K Cochran, C Cameron, E Wang, PW Schow, ... | 271 | 1992 |
| Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the … T Prebet, Z Sun, ME Figueroa, R Ketterling, A Melnick, PL Greenberg, ... Journal of Clinical Oncology 32 (12), 1242-1248, 2014 | 261 | 2014 |
| Evolution of acute myelogenous leukemia stem cell properties after treatment and progression TC Ho, M LaMere, BM Stevens, JM Ashton, JR Myers, KM O’Dwyer, ... Blood, The Journal of the American Society of Hematology 128 (13), 1671-1678, 2016 | 254 | 2016 |
| A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer M Aglietta, C Barone, MB Sawyer, MJ Moore, WH Miller Jr, C Bagalà, ... Annals of oncology 25 (9), 1750-1755, 2014 | 237 | 2014 |
| Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial S Faderl, M Wetzler, D Rizzieri, G Schiller, M Jagasia, R Stuart, S Ganguly, ... Journal of clinical oncology 30 (20), 2492-2499, 2012 | 209 | 2012 |
| Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency … ES Wang, DJ Straus, J Teruya‐Feldstein, J Qin, C Portlock, C Moskowitz, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 199 | 2003 |
| Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo ES Wang, J Teruya-Feldstein, Y Wu, Z Zhu, DJ Hicklin, MAS Moore Blood 104 (9), 2893-2902, 2004 | 185 | 2004 |
| Acute myeloid leukemia, version 2.2013 MR O’Donnell, MS Tallman, CN Abboud, JK Altman, FR Appelbaum, ... Journal of the National Comprehensive Cancer Network 11 (9), 1047-1055, 2013 | 182 | 2013 |
| Philadelphia chromosome‐positive acute lymphoblastic leukemia: Current treatment and future perspectives HJ Lee, JE Thompson, ES Wang, M Wetzler Cancer 117 (8), 1583-1594, 2011 | 175 | 2011 |
| Phase 2 study of romiplostim in patients with low-or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy HM Kantarjian, FJ Giles, PL Greenberg, RL Paquette, ES Wang, ... Blood, The Journal of the American Society of Hematology 116 (17), 3163-3170, 2010 | 169 | 2010 |
| NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018 RA Mesa, C Jamieson, R Bhatia, MW Deininger, CD Fletcher, AT Gerds, ... Journal of the National Comprehensive Cancer Network 15 (10), 1193-1207, 2017 | 159 | 2017 |
